Skip to main content

Table 2 Differences between study variables from 6 months prior to enrollment, baseline and month 6

From: Diabetic macular edema treated with intravitreal aflibercept injection after treatment with other anti-VEGF agents (SWAP-TWO study): 6-month interim analysis

Factor 6 Months prior to enrollment Baseline Month 6 95% CI for changes 6 Months prior to enrollment to baseline Baseline to month 6
[Mean ± SD] [Mean ± SD] [Mean ± SD]   P value P value
ETDRS BCVA 70.1 ± 7.7 70.0 ± 7.2 71.5 ± 8.9 1.55 (− 2.08, 5.18) 0.95 0.38
Central subfield thickness (µm) 420.8 ± 100.5 419.7 ± 92.0 303.8 ± 73.1 − 116.0 (− 150.8, − 81.15) 0.99 <  0.001
Cube volume (mm3) N/A 11.5 ± 1.4 10.7 ± 1.2 − 0.86 (− 1.06, − 0.65) N/A <  0.001
Cube average thickness (µm) N/A 320.7 ± 38.6 297.2 ± 33.1 − 23.50 (− 29.36, − 17.64) N/A <  0.001
Foveal avascular zone (mm2) N/A 0.31 ± 0.13 0.33 ± 0.11a − 0.03(− 0.11, 0.05) N/A 0.47
  1. Statistically significant values are in bold italic
  2. ETDRS early treatment diabetic retinopaty study, BCVA best corrected visual acuity, CI confidence interval
  3. an = 18